Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) Profit After Tax (2016 - 2025)

Historic Profit After Tax for CorMedix (CRMD) over the last 14 years, with Q3 2025 value amounting to $108.6 million.

  • CorMedix's Profit After Tax rose 400962.66% to $108.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.5 million, marking a year-over-year increase of 49500.26%. This contributed to the annual value of -$17.9 million for FY2024, which is 6130.7% up from last year.
  • As of Q3 2025, CorMedix's Profit After Tax stood at $108.6 million, which was up 400962.66% from $19.8 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Profit After Tax ranged from a high of $108.6 million in Q3 2025 and a low of -$14.5 million during Q1 2024
  • For the 5-year period, CorMedix's Profit After Tax averaged around $2.3 million, with its median value being -$7.4 million (2021).
  • Per our database at Business Quant, CorMedix's Profit After Tax tumbled by 6414.73% in 2022 and then skyrocketed by 400962.66% in 2025.
  • Quarter analysis of 5 years shows CorMedix's Profit After Tax stood at -$7.8 million in 2021, then dropped by 5.36% to -$8.2 million in 2022, then decreased by 18.7% to -$9.7 million in 2023, then surged by 238.18% to $13.5 million in 2024, then skyrocketed by 706.3% to $108.6 million in 2025.
  • Its Profit After Tax was $108.6 million in Q3 2025, compared to $19.8 million in Q2 2025 and $20.6 million in Q1 2025.